AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 52 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $187,479 | -5.5% | 646,478 | +46.6% | 0.03% | -27.9% |
| Q4 2022 | $198,333 | -84.5% | 440,837 | +135.5% | 0.04% | -75.4% |
| Q2 2019 | $1,282,000 | -83.7% | 187,206 | -80.8% | 0.18% | -75.6% |
| Q1 2019 | $7,849,000 | +74.7% | 975,000 | +62.5% | 0.72% | +41.2% |
| Q4 2018 | $4,494,000 | -28.1% | 600,000 | -8.1% | 0.51% | -29.4% |
| Q3 2018 | $6,250,000 | +16.0% | 653,112 | +28.3% | 0.72% | -3.4% |
| Q2 2018 | $5,386,000 | – | 509,118 | – | 0.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |